CN114832042A - Traditional Chinese medicine composition and application thereof in preparation of medicine for treating blood sugar reduction - Google Patents
Traditional Chinese medicine composition and application thereof in preparation of medicine for treating blood sugar reduction Download PDFInfo
- Publication number
- CN114832042A CN114832042A CN202210453985.8A CN202210453985A CN114832042A CN 114832042 A CN114832042 A CN 114832042A CN 202210453985 A CN202210453985 A CN 202210453985A CN 114832042 A CN114832042 A CN 114832042A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- parts
- chinese medicinal
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 210000004369 blood Anatomy 0.000 title claims abstract description 39
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims description 9
- 230000009467 reduction Effects 0.000 title abstract description 4
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 14
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 14
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract 3
- 239000000284 extract Substances 0.000 claims description 19
- 241001264174 Cordyceps militaris Species 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003472 antidiabetic agent Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 238000005189 flocculation Methods 0.000 claims description 2
- 230000016615 flocculation Effects 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 238000000199 molecular distillation Methods 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 238000001256 steam distillation Methods 0.000 claims description 2
- 238000000859 sublimation Methods 0.000 claims description 2
- 230000008022 sublimation Effects 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- 239000012676 herbal extract Substances 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000006870 function Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 33
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 18
- 239000008103 glucose Substances 0.000 description 18
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 10
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 9
- 229930186217 Glycolipid Natural products 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000000465 moulding Methods 0.000 description 5
- 238000007410 oral glucose tolerance test Methods 0.000 description 5
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 4
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 102100027441 Nucleobindin-2 Human genes 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000016097 disease of metabolism Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000686 essence Substances 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023388 Ketonuria Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001657948 Midea Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000012874 Phaseolus calcaratus Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000185386 Thladiantha grosvenorii Species 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition and application thereof in preparing a hypoglycemic medicament. The application is the application of the traditional Chinese medicine composition in preparing medicines for treating blood sugar reduction and/or health care products. According to the traditional Chinese medicine composition, cyclocarya paliurus, the root of kudzu vine and the fingered citron are selected as main raw materials, the effects of reducing blood sugar and repairing pancreas islet functions are achieved through the synergistic effect of the three raw materials, the traditional Chinese medicine composition has the advantages of safety and no stimulation, and can be used for a long time.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition and application thereof in preparation of a medicine for treating blood sugar reduction.
Background
Diabetes mellitus is a common endocrine disease which is mainly characterized by chronic hyperglycemia, glycolipid metabolism and protein metabolism disorder, and the pathogenesis of diabetes mellitus is mainly due to absolute insufficient insulin secretion and islet resistance. When insulin is insufficient, the serum glucose content is continuously increased and exceeds the reabsorption capability of the kidney, so that a large amount of glucose is excreted along with urine, osmotic diuresis is caused, the body is dehydrated, brain cells lose water, brain dysfunction can be caused to be coma, and because a diabetic patient has sugar utilization disorder, energy is generated by decomposing fat, and the generation of ketone bodies is increased along with the fat decomposition, so that diabetic ketoacidosis is caused. Research shows that oxidative stress is closely related to the formation of diabetes, and excessive free radical generation by oxidative stress can cause the functional damage of islet beta cells, insufficient insulin secretion and peripheral insulin resistance, induce the formation of diabetes, and cause various complications such as diabetic neuropathy, diabetic retinopathy, diabetic cardiovascular and cerebrovascular diseases and the like.
Most of the hypoglycemic drugs commonly used in clinical practice are chemically synthesized drugs (such as alpha-glycosidase inhibitors). The toxic effects of enteroglycosidases through inhibition of hyperglycemia are associated not only with prolonged elevated blood glucose, but also with the relative levels of postprandial elevated blood glucose. After entering the small intestine, the polysaccharides in the food are degraded into some oligosaccharides and disaccharides by amylase, and then decomposed into monosaccharides by alpha-glucosidase at the brush border of the small intestine to be absorbed into the blood. Competitive inhibition of small intestinal glucosidase therefore reduces postprandial hyperglycemia levels. However, these drugs can cause serious adverse reactions when taken for a long time, such as: nausea, vomiting, abdominal discomfort, and the like, as well as leukopenia, ketonuria, lactic acidosis, and the like, have limited applications. The research and development of natural antidiabetic drugs with high efficiency, low toxicity and low price for reducing blood sugar to relieve diabetic complications is a problem to be solved urgently in clinic. Therefore, the search of high-efficiency hypoglycemic drugs from plants becomes one of the key points of the research of antidiabetic drugs at home and abroad.
CN106924479A discloses a traditional Chinese medicine composition for reducing blood sugar, which comprises the following traditional Chinese medicines in parts by mass: 16-20 parts of kudzuvine root, 16-20 parts of astragalus, 16-20 parts of hairyvein agrimony, 15-19 parts of mulberry leaf, 15-19 parts of tuber fleeceflower root, 15-19 parts of pine pollen, 14-18 parts of medlar, 14-18 parts of Chinese magnoliavine fruit, 14-18 parts of glossy privet fruit, 12-14 parts of cortex moutan, 12-14 parts of szechwan chinaberry fruit, 12-14 parts of tuber fleeceflower root, 10-12 parts of liquorice, 10-12 parts of green plum blossom, 8-10 parts of spina date seed, 5-7 parts of momordica grosvenori, 5-7 parts of honeysuckle, 3-5 parts of cyclocarya paliurus leaves, 1-3 parts of Chinese yam and 1-3 parts of szechuan lovage rhizome. The traditional Chinese medicine composition for reducing blood sugar is natural and safe, and can reduce the blood sugar level of a diabetic patient and improve the symptoms of the diabetic patient.
CN108272984A discloses a medicine for reducing blood sugar, which comprises the following raw materials in parts by weight: 16-22 parts of cyclocarya paliurus, 6-10 parts of kudzu root, 3-5 parts of phaseolus calcaratus, 5-8 parts of radix rehmanniae recen, 4-6 parts of asparagus, 10-15 parts of cucumber, 8-14 parts of bitter gourd, 1.8-4 parts of grandma and 4-8 parts of coptis chinensis.
According to the traditional Chinese medicine, the 'turbid glycolipid metabolic disease' is a disease which takes emotional disorder, improper diet, insufficient innate endowment or senile asthenia as main causes, liver dysfunction as a core pathogenesis, damp, phlegm, stasis, heat and toxin as main pathological products, and depression or irritability, obesity or emaciation, heavy head and body, bitter taste and sticky mouth, chest and hypochondrium swelling or pain, fatigue and hypodynamia, dry throat and dry mouth and other main clinical manifestations. Clinically, the "fever" and the "turbidity" are often seen mutually, and are mutually interwoven and mutually influenced, so the combined use of the turbidity is taken as a disease covering the pathological changes of hyperglycemia, hyperlipidemia, atheromatous plaque, vascular injury and the like caused by the disorder of the glycometabolism and the lipotropia and the multi-organ affected characteristics thereof.
The invention starts the spleen pivot qi movement to go up and down and come in and go out by regulating the liver function, and regulates the metabolism of essence, blood and body fluid to dispel damp phlegm and turbid blood stasis, thereby correcting the in vivo glycolipid metabolic disturbance and realizing the purpose of comprehensively regulating and controlling the glycolipid metabolic disease (fever).
Disclosure of Invention
In view of the above, the invention provides a traditional Chinese medicine composition and an application thereof in preparing a hypoglycemic medicament.
In order to achieve the purpose, the invention adopts the following technical scheme:
a Chinese medicinal composition comprises cyclocarya paliurus, radix Puerariae and fructus Citri Sarcodactylis.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-20 parts of cyclocarya paliurus, 10-30 parts of kudzu root and 8-36 parts of fingered citron.
Preferably, the traditional Chinese medicine composition further comprises cordyceps militaris.
Further preferably, the cordyceps militaris is 5-15 parts by weight.
The kudzu root in the invention can also be kudzu, the technical effects of the invention can be realized by the technical schemes, and in some preferred embodiments, the achieved technical effects are superior to other schemes.
For example:
the mass ratio of cyclocarya paliurus to radix puerariae is 1: 1, wherein the preferable traditional Chinese medicine composition comprises the following specific components in parts by weight: 10 parts of cyclocarya paliurus, 10 parts of kudzu root and 10 parts of fingered citron.
The mass ratio of cyclocarya paliurus, the radix puerariae and the cordyceps militaris is 7: 7: 6, one of the preferable traditional Chinese medicine compositions comprises the following specific components in parts by weight: 14 parts of cyclocarya paliurus, 14 parts of kudzu root, 24 parts of fingered citron and 12 parts of cordyceps militaris.
The invention also provides a traditional Chinese medicine extract which is extracted from the traditional Chinese medicine composition.
Preferably, the extraction is: the extraction method comprises at least one of water decoction, soaking, percolation, modified gelatin, reflux, solvent extraction, steam distillation, sublimation, supercritical fluid extraction, membrane separation, micronization, flocculation separation of Chinese medicinal materials, semi-bionic extraction, ultrasonic extraction, cyclone extraction, pressurized countercurrent extraction, enzyme method, macroporous resin adsorption, ultrafiltration, and molecular distillation.
The invention provides a method for preparing the traditional Chinese medicine extract, which comprises the following steps: extracting the raw materials according to the formula amount with water, combining the filtrates, concentrating under reduced pressure to obtain dry extract, and pulverizing to obtain the traditional Chinese medicine extract.
The invention also provides a medicament which comprises the traditional Chinese medicine composition, the traditional Chinese medicine extract or the traditional Chinese medicine extract prepared by the preparation method.
The invention also provides the application of the traditional Chinese medicine composition, the traditional Chinese medicine extract or the traditional Chinese medicine extract prepared by the preparation method in preparing medicines and/or health-care products for reducing blood sugar.
The invention has the beneficial effects that: (1) compared with the dialectical theory of treating diabetes from the spleen in the prior art, the traditional Chinese medicine composition disclosed by the invention selects cyclocarya paliurus, the root of kudzu vine and the fingered citron as main raw materials, starts the spleen pivot qi movement to go up and down and come in and out by regulating the function of the liver, and regulates the metabolism of essence, blood and body fluid to dispel damp phlegm and turbid blood stasis, so that the metabolic disorder of glycolipid in vivo is corrected, and the purpose of comprehensively regulating and controlling the glycolipid metabolism (turbid pathogen) is realized.
(2) The invention exerts better effects of reducing blood sugar and repairing insulin functions through the synergistic effect of the three raw materials, has no damage to liver and kidney in the taking process, has certain effect of protecting liver, has the advantages of safety and no stimulation, and can be used for a long time.
(3) When a specific amount of cordyceps militaris is added, a synergistic effect can be further exerted, and the islet cell recovery level is improved.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
Before the present embodiments are further described, it is to be understood that the scope of the invention is not limited to the particular embodiments described below; it is also to be understood that the terminology used in the examples is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention.
When numerical ranges are given in the examples, it is understood that both endpoints of each of the numerical ranges and any value therebetween can be selected unless the invention otherwise indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The sources of the raw materials used in the present invention are not limited, and the raw materials used in the present invention are all those commonly available in the art unless otherwise specified. The cyclocarya paliurus adopted by the implementation is cyclocarya paliurus leaves.
Basic embodiment
A traditional Chinese medicine composition comprises the following raw materials: cyclocarya paliurus, radix puerariae and fingered citron.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 5-20 parts of cyclocarya paliurus, 10-30 parts of kudzu root and 8-36 parts of fingered citron.
Preferably, the traditional Chinese medicine composition further comprises cordyceps militaris.
Further preferably, the cordyceps militaris is 5-15 parts by weight.
The technical effects of the invention can be realized by the technical schemes, and in some preferred embodiments, the achieved technical effects are superior to other schemes.
For example:
the mass ratio of cyclocarya paliurus to radix puerariae is 1: 1, wherein the preferable traditional Chinese medicine composition comprises the following specific components in parts by weight: 10 parts of cyclocarya paliurus, 10 parts of kudzu root and 10 parts of fingered citron.
The mass ratio of cyclocarya paliurus, the radix puerariae and the cordyceps militaris is 7: 7: 6, one of the preferable traditional Chinese medicine compositions comprises the following specific components in parts by weight: 14 parts of cyclocarya paliurus, 14 parts of kudzu root, 24 parts of fingered citron and 12 parts of cordyceps militaris.
Examples and comparative examples A Chinese medicinal composition and method for preparing the same
The raw materials and the amounts (parts by weight) of the Chinese medicinal compositions described in examples 1 to 6 and comparative examples 1 to 2 are shown in Table 1.
TABLE 1
Remarking: in the table, "+" represents 12 parts of mulberry leaves and "-" represents no addition.
The preparation method comprises the following steps: taking raw materials according to the prescription amount, mixing and extracting for 2 times, adding 10 times of water (weight of the prescription amount) for the first time, and extracting for 2 hours; filtering, adding 8 times of water (formula weight amount) into the residue, extracting for 1 hr, filtering, mixing filtrates, concentrating under reduced pressure to obtain dry extract, and pulverizing.
Evaluation of efficacy
1 materials of the experiment
The Chinese medicinal compositions prepared in examples 1-6 and comparative examples 1-2.
2 laboratory animals
Experimental animals 4 weeks old, male, healthy C57BL/6J mice, weighing 18-25g, were obtained.
3 Main Equipment, Instrument and consumables
Blood glucose meters (roche); glucose kit (Glu, shanghai nabobism pharmaceutical limited); triglyceride reagent kit (TG, Nanjing institute of bioengineering); a total cholesterol kit (TC, Nanjing institute of bioengineering); high density lipoprotein kit (HDL-C, Nanjing institute of bioengineering); low density lipoprotein kit (LDL-C, Nanjing institute of bioengineering); free fatty acid kit (NEFA, Nanjing institute of bioengineering); mouse Insulin (INS) ELISA kit (brilliant); streptozotocin (STZ, Sigma, usa); citric acid and sodium citrate (guangzhou ruishu biotechnology limited); metformin (shanghai shigui pharmaceutical ltd, midea); glucose (Tianjin Jianyun chemical Co., Ltd.); absolute ethanol (Tianjin Chengyuan chemical reagent, Inc.); d101 macroporous adsorption resin (Dongpo chemical Co., Ltd.).
4 Experimental methods
4.1 random grouping
One week after acclimation feeding, all mice were randomly assigned to the following 2 groups according to body weight by the random number table method: blank control group 10, T2DM group 100. After the T2DM group molding was successful, the following 10 groups were randomly assigned according to blood glucose levels: model group (10), examples 1-6 groups (10 each), comparative examples 1-2 groups (10 each), and positive drug group (10). Mice in the placebo group and High Fat Diet (HFD) fed (60% cholesterol) T2DM group were fed with normal diet.
4.2 Molding method and pharmaceutical intervention
Molding a mouse, after fasting for 12 hours, dissolving the STZ in a citric acid buffer solution (PH4.2) with the concentration of 0.1mmol/L according to the daily dosage of 40mg/kg of body weight, and performing intraperitoneal injection on the mouse; the blank group was injected 1ml/100g of citrate buffer 1 time daily for 4 consecutive days. Blood glucose was measured 72 hours after molding. After the blood sugar rises and stabilizes for 2 weeks, the mice with the concentration more than or equal to 11.1mmol/L are successfully modeled. After 2 weeks, randomly selecting 3 rats for liver pathological observation, wherein liver steatosis occurs to a certain extent, a large amount of lipid drop vacuoles appear in cytoplasm, and measuring Fasting Blood Glucose (FBG) of the rats for more than 2 times is more than or equal to 11.1mmol/L, which indicates that T2DM molding is successful.
According to the clinical dose combination preliminary experiment, the administration dose of the example group and the comparative example group was set as: 1.2g crude drug/kg, the administration mode is intragastric; metformin tablet 250mg/kg (formulated as 100g/L aqueous solution) was administered by gavage at 1mL/100g/d for 12 weeks.
5 index measuring method
5.1 Oral Glucose Tolerance Test (OGTT) test
The feed of the mice is taken out 6 hours in advance, water is normally supplied, and the padding is replaced, because the blood sugar of the mice can be influenced by the feed residues in the padding. The glucose content was measured by gavage at 1.5g/kg and 1ml/100g at 0, 30, 60, 90, 120, 150 min and other time points.
5.2 insulin glucose tolerance test (ITT) test
Fasting is not forbidden for 6 h. Mice were weighed and insulin doses were calculated at 0.5U/kg, insulin being pre-prepared at 0.05U/ml. Blood glucose of each mouse was measured to obtain a blood glucose value at time 0, and then insulin was intraperitoneally injected, and tail blood samples were collected at 15, 30, 60, 90, and 120 minutes after the injection and blood glucose was measured using a glucometer, respectively.
5.3 plasma sample index detection
Mouse FBG was detected at the same time every week. According to the kit specification, the content of HDL-C, LDL-C, NEFA in serum is measured by a direct method, and the TC and TG levels in the serum are measured by a micro-method; plasma INS levels were measured by ELISA and the insulin resistance index (HOMA-IR) was calculated. After the administration, the mice are fasted for 6h, the mice are anesthetized by ether after weighing, the eyeballs are picked up and blood is taken out of a 1.5ml EP tube, the centrifugation is carried out for 10min at 4 ℃ and 3500r/min, and the plasma is separated and frozen at minus 80 ℃ for standby.
Calculating by the formula: insulin resistance index (HOMA-IR) ═ fasting insulin INS × fasting glucose/22.5.
5.4 statistical analysis
Data were analyzed using GraphPad Prism 8.0 software using the two-tailed unpaired Student's t test for comparisons between groups and One-way ANOVA test for more than two groups, with data expressed as Mean ± standard error (Mean ± SEM).
6 results of the experiment
6.1 Effect on mice fasting insulin resistance index, oral glucose tolerance (OGTT) and insulin glucose tolerance
Compared with the blank mice, the fasting insulin resistance index (HOMA-IR) of the model mice has obvious rising change (P is less than 0.001), which indicates that the model building is successful.
Compared with the mice in the model group, the fasting insulin resistance indexes of the mice in the positive drug group, the mice in the example 5 group and the mice in the example 6 group are all reduced, and the significant difference is realized (P is less than 0.05); compared with the model group mice, the fasting insulin resistance indexes of the mice in the positive drug group, the mice in the example 3 group and the mice in the 4 group are all reduced, and the significant difference is shown (P is less than 0.01).
Compared with the blank mice, the area under the OGTT curve of the model mice is obviously increased (P is less than 0.001), which indicates that the model building is successful.
Compared with the mice in the model group, the areas under the OGTT curves of the mice in the positive drug group, the mice in the groups of examples 1-6 and the mice in the comparative example 2 are obviously reduced, and the significant difference is achieved (P is less than 0.05).
Compared with the blank mice, the ITT of the model mice has obvious increase change (P is less than 0.001), which indicates that the modeling is successful.
Compared with the mice in the model group, the ITT of the mice in the positive medicine group and the mice in the example 4 is remarkably reduced (P is less than 0.001); the ITT was significantly reduced in the mice of example 3, 5 and 6 groups compared to the mice of the model group (P < 0.01).
TABLE 1 Effect of Chinese medicinal compositions on mouse OGTT, ITT and HOMA-IR (x + -SEM, n ═ 10)
6.2 Effect on blood indices in T2DM mice
Compared with a blank control group, the Total Cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) level of the model group mouse is obviously increased (P is less than 0.001), and the high-density lipoprotein cholesterol (HDL-C) level is obviously reduced (P is less than 0.001); free fatty acid (NEFA) levels were significantly elevated (P < 0.05).
The group of positive drugs, examples 1 to 6 and comparative example 2 significantly reduced Total Cholesterol (TC), Triglyceride (TG) and free fatty acid (NEFA) in T2DM mice and increased high density lipoprotein cholesterol (HDL-C) levels, compared to the model group.
Table 2 effect of the Chinese medicinal composition on blood index of T2DM mouse (x ± SEM, n ═ 10)
The results show that the traditional Chinese medicine composition can obviously improve the blood sugar and blood fat metabolism of the STZ-induced diabetic mice, reduce the fasting blood sugar and blood fat levels of the diabetic mice, increase the glucose tolerance and insulin resistance, and partially recover the islet cells to normal level, thereby maintaining the islet function and regulating the glycolipid metabolic disorder.
According to the traditional Chinese medicine composition, cyclocarya paliurus, the root of kudzu vine and the fingered citron are selected as main raw materials, the spleen pivot qi activity is started to go up and down through the function of regulating the liver, the essence, blood and body fluid metabolism is regulated, and the damp phlegm and turbid blood stasis is removed, so that the in-vivo glycolipid metabolic disturbance is corrected, the purpose of comprehensively regulating and controlling the glycolipid metabolic disease (turbid fever) is realized, meanwhile, the traditional Chinese medicine composition has no harm to the liver and the kidney in the taking process, and has a certain liver protection effect. Meanwhile, when a specific amount of cordyceps militaris is added into the composition of cyclocarya paliurus, radix puerariae and fingered citron, the synergistic effect can be further exerted, and the recovery level of islet cells is improved.
The present invention has been further described with reference to specific embodiments, which are only exemplary and do not limit the scope of the present invention. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Claims (10)
1. A Chinese medicinal composition is characterized by comprising cyclocarya paliurus, radix puerariae and fingered citron.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 5-20 parts of cyclocarya paliurus, 10-30 parts of kudzu root and 8-36 parts of fingered citron.
3. The traditional Chinese medicine composition of claim 1, further comprising cordyceps militaris.
4. The traditional Chinese medicine composition as claimed in claim 3, wherein the cordyceps militaris is 5-15 parts by weight.
5. A Chinese medicinal extract, which is obtained by extracting the Chinese medicinal composition of any one of claims 1 to 4.
6. The herbal extract as claimed in claim 5, wherein the extraction is: the extraction method comprises at least one of water decoction, soaking, percolation, modified gelatin, reflux, solvent extraction, steam distillation, sublimation, supercritical fluid extraction, membrane separation, micronization, flocculation separation of Chinese medicinal materials, semi-bionic extraction, ultrasonic extraction, cyclone extraction, pressurized countercurrent extraction, enzyme method, macroporous resin adsorption, ultrafiltration, and molecular distillation.
7. A method for preparing the traditional Chinese medicine extract of claim 5, which is characterized by comprising the following steps: extracting the raw materials according to the formula amount with water, combining the filtrates, concentrating under reduced pressure to obtain dry extract, and pulverizing to obtain the traditional Chinese medicine extract.
8. A hypoglycemic agent comprising the Chinese medicinal composition according to any one of claims 1 to 4, the Chinese medicinal extract according to claim 5, or the Chinese medicinal extract prepared by the production method according to claim 7.
9. A health product for reducing blood sugar, which is characterized by comprising the traditional Chinese medicine composition of any one of claims 1 to 4, the traditional Chinese medicine extract of claim 5 or the traditional Chinese medicine extract prepared by the preparation method of claim 7.
10. Use of the Chinese medicinal composition according to any one of claims 1 to 4, the Chinese medicinal extract according to claim 5 or the Chinese medicinal extract prepared by the preparation method according to claim 7 in the preparation of hypoglycemic drugs and/or health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210453985.8A CN114832042B (en) | 2022-04-24 | 2022-04-24 | Traditional Chinese medicine composition and application thereof in preparation of medicines for treating blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210453985.8A CN114832042B (en) | 2022-04-24 | 2022-04-24 | Traditional Chinese medicine composition and application thereof in preparation of medicines for treating blood sugar |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114832042A true CN114832042A (en) | 2022-08-02 |
| CN114832042B CN114832042B (en) | 2023-08-22 |
Family
ID=82566872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210453985.8A Active CN114832042B (en) | 2022-04-24 | 2022-04-24 | Traditional Chinese medicine composition and application thereof in preparation of medicines for treating blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114832042B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103931852A (en) * | 2014-05-15 | 2014-07-23 | 南京裕垄农业发展有限公司 | Cyclocarya paliurus and cordyceps militaris composite tea bag and preparation method thereof |
| CN104839656A (en) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Liver disease medicine formula food |
| CN107156828A (en) * | 2017-01-18 | 2017-09-15 | 恩施硒域传奇健康管理有限公司 | A kind of full nutrition formula food suitable for patients with inflammatory bowel |
| CN110150415A (en) * | 2019-06-20 | 2019-08-23 | 珠海林尚熙养生茶业有限公司 | A kind of three high tea-drinkings and preparation method thereof of tranquilizing the mind defaecation prevention |
| CN111568945A (en) * | 2020-04-02 | 2020-08-25 | 湖南清雅健康服务有限公司 | Compound cyclocarya paliurus preparation |
| CN112516206A (en) * | 2020-12-24 | 2021-03-19 | 中国科学院城市环境研究所 | Composition for reducing high blood pressure, high blood sugar and high blood fat, traditional Chinese medicine preparation and application |
-
2022
- 2022-04-24 CN CN202210453985.8A patent/CN114832042B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103931852A (en) * | 2014-05-15 | 2014-07-23 | 南京裕垄农业发展有限公司 | Cyclocarya paliurus and cordyceps militaris composite tea bag and preparation method thereof |
| CN104839656A (en) * | 2015-04-10 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Liver disease medicine formula food |
| CN107156828A (en) * | 2017-01-18 | 2017-09-15 | 恩施硒域传奇健康管理有限公司 | A kind of full nutrition formula food suitable for patients with inflammatory bowel |
| CN110150415A (en) * | 2019-06-20 | 2019-08-23 | 珠海林尚熙养生茶业有限公司 | A kind of three high tea-drinkings and preparation method thereof of tranquilizing the mind defaecation prevention |
| CN111568945A (en) * | 2020-04-02 | 2020-08-25 | 湖南清雅健康服务有限公司 | Compound cyclocarya paliurus preparation |
| CN112516206A (en) * | 2020-12-24 | 2021-03-19 | 中国科学院城市环境研究所 | Composition for reducing high blood pressure, high blood sugar and high blood fat, traditional Chinese medicine preparation and application |
Non-Patent Citations (2)
| Title |
|---|
| 佚名: "中药"调肝"可提高糖脂代谢病疗效", vol. 47, no. 3, pages 64 * |
| 张磊: "基于网络药理学的佛手干预2型糖尿病潜在靶点机制研究", vol. 22, no. 10, pages 3594 - 3604 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114832042B (en) | 2023-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN103041118A (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN102652801A (en) | Chinese herbal medicine tea bag for lowering blood sugar and preventing diabetes mellitus complications | |
| CN109718273B (en) | Application of perilla leaf extract in preventing or treating osteoarthritis | |
| CN1382478A (en) | Extract of mulberry twig and its extracting process and novel usage | |
| CN108434191B (en) | Composition with weight-losing and lipid-lowering effects and preparation method thereof | |
| CN114832042A (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating blood sugar reduction | |
| CN102631482B (en) | Chinese medicinal composition for preventing and treating diabetes and complications | |
| CN105456689A (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation method and application of traditional Chinese medicine composition | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| CN104013696B (en) | A kind of plant drug composition of preventing and treating metabolism syndrome and its application | |
| CN107875350B (en) | A Chinese medicinal composition for treating diabetes | |
| CN108498563B (en) | Chitosan composition and preparation method thereof | |
| CN111643540A (en) | Eucommia ulmoides extract for treating lumbar muscle strain and preparation method thereof | |
| CN112057559A (en) | Application of dendrobium huoshanense extract in medicine for preventing, relieving and/or treating uric acid renal disease | |
| KR20100072709A (en) | Composition for preventing and treating diabetics by hyperglycemic action | |
| CN105935375A (en) | Application of Quanmasu in preparation of anti-aging drugs | |
| CN114272295A (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN101745011B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN104940428B (en) | Hypoglycemic composition containing wolfberry fruits and application thereof | |
| CN113713016B (en) | Application of seville orange flower in preparation of medicine for improving fatty liver | |
| CN103735591B (en) | A kind of compositions of anti-peptic ulcer and application thereof | |
| CN109125623A (en) | It is a kind of for treating the pharmaceutical composition of hepatopathy | |
| TWI387461B (en) | Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230407 Address after: No. 43-9085 Guangrao Road, Shibei District, Qingdao City, Shandong Province, 266023 Applicant after: Qingdao Lianhuasheng Medical Technology Co.,Ltd. Address before: 510006 Panyu District, Guangzhou, Guangdong, 280 Panyu District road outside the city. Applicant before: GUANGDONG PHARMACEUTICAL University |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231206 Address after: 910-A49, Building 5, Xiangtai Square, No. 129 Yingxiong Mountain Road, Liulishan Street, Shizhong District, Jinan City, Shandong Province, 250001 Patentee after: Jinan Changgeng Pharmaceutical Technology Co.,Ltd. Address before: No. 43-9085 Guangrao Road, Shibei District, Qingdao City, Shandong Province, 266023 Patentee before: Qingdao Lianhuasheng Medical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |